Skip to content

Value of Presepsin and MR-ProADM in the diagnosis and prognosis assessment of sepsis in children

Value of Presepsin and MR-ProADM in the diagnosis and prognosis assessment of sepsis in children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061098
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

case series:case series
healthy control group:Nil

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Experimental group: (1) Children who are admitted to PICU directly from the outpatient/emergency department; (2) Children with sepsis meet the diagnostic criteria for sepsis; (3) Aged < 18 years (except newborns); (4) Complete clinical data; (5) Informed consent of the child's family or guardian. 2. Control group: (1) Healthy children; (2) Aged < 18 years (except newborns).

Exclusion criteria

Exclusion criteria: 1. Experimental group: (1) Children transferred from other departments to PICU; (2) Those who have not collected blood within 24 hours of admission to the hospital. 2. Control group: those who have abnormal results in any physical examination.

Design outcomes

Primary

MeasureTime frame
MR-ProADM;Presepsin;

Countries

China

Contacts

Public ContactXu Feng
Xufeng9899@163.com+86 15320206699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026